Type 1 diabetes and interferon therapy: A nationwide survey in Japan

Diabetes Care

Volumn 34, Issue 9, 2011, Pages 2084-2089

  Nakamura, Kan ^a   Kawasaki, Eiji ^a   Imagawa, Akihisa ^b   Awata, Takuya ^c   Ikegami, Hiroshi ^d   Uchigata, Yasuko ^e   Kobayashi, Tetsuro ^f   Shimada, Akira ^g   Nakanishi, Koji ^h   Makino, Hideichi ⁱ   Maruyama, Taro ^j   Hanafusa, Toshiaki ^k  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^f UNIVERSITY OF YAMANASHI   (Japan)

^g SAISEIKAI CENTRAL HOSPITAL   (Japan)

^h Okinaka Memorial Institute for Medical Research   (Japan)

ⁱ Diabetes Center   (Japan)

^j Saitama Social Insurance Hospital   (Japan)

^k OSAKA MEDICAL COLLEGE   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; HLA DR ANTIGEN; HLA DR13 ANTIGEN; HLA DR4 ANTIGEN; HLA DR6 ANTIGEN; INSULIN; INTERFERON; PANCREAS ISLET CELL ANTIBODY; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; UNCLASSIFIED DRUG; ANTIVIRUS AGENT; HLA DR9 ANTIGEN; HLA-DR13 ANTIGEN; HLA-DR9 ANTIGEN;

ADULT; ARTICLE; BODY MASS; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; FEMALE; HEPATITIS B; HEPATITIS C; HLA TYPING; HUMAN; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; JAPAN; JAPANESE; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; CHEMICALLY INDUCED DISORDER; METABOLISM; MIDDLE AGED;

ANTIVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HLA-DR SEROLOGICAL SUBTYPES; HLA-DR4 ANTIGEN; HUMANS; INTERFERONS; JAPAN; MALE; MIDDLE AGED; RIBAVIRIN;

EID: 84859845745     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-2274     Document Type: Article

References (25)

1. Sato K, Hida S, Takayanagi H, et al. Antiviral response by natural killer cells through TRAIL gene induction by interferon-alpha/beta. Eur J Immunol 2001;31:3138-3146 (Pubitemid 33100505)
2. Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid 2003;13:547-551
3. Fabris P, Betterle C, Floreani A, et al. Development of type 1 diabetes mellitus during interferon alpha therapy for chronic HCV hepatitis. Lancet 1992;340:548
4. Waguri M, Hanafusa T, Itoh N, et al. Occurrence of IDDM during interferon therapy for chronic viral hepatitis. Diabetes Res Clin Pract 1994;23:33-36 (Pubitemid 24118512)
5. Guerci AP, Guerci B, Levy-Marchal C, et al. Onset of insulin-dependent diabetes mellitus after interferon-alpha therapy for hairy cell leukemia. Lancet 1994;343:1167-1168
6. Cozzolongo R, Betterle C, Fabris P, Paola Albergoni M, Lanzilotta E, Manghisi OG. Onset of type 1 diabetes mellitus during peginterferon alpha-2b plus ribavirin treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2006;18:689-692 (Pubitemid 43804655)
7. Schreuder TC, Gelderblom HC, Weegink CJ, et al. High incidence of type 1 diabetes mellitus during or shortly after treatment with pegylated interferon alpha for chronic hepatitis C virus infection. Liver Int 2008;28:39-46
8. Bosi E, Minelli R, Bazzigaluppi E, Salvi M. Fulminant autoimmune type 1 diabetes during interferon-alpha therapy: a case of Th1-mediated disease? Diabet Med 2001;18:329-332 (Pubitemid 32579365)
9. Piquer S, Hernandez C, Enriquez J, et al. Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: effect of treatment with interferon. J Lab Clin Med 2001;137:38-42 (Pubitemid 32102754)
10. Yamazaki M, Sato A, Takeda T, Komatsu M. Distinct clinical courses in type 1 diabetes mellitus induced by peg-interferon-alpha treatment for chronic hepatitis C. Intern Med 2010;49:403-407
11. Kawasaki E, Matsuura N, Eguchi K. Type 1 diabetes in Japan. Diabetologia 2006;49:828-836
12. Sera Y, Kawasaki E, Abiru N, et al. Autoantibodies to multiple islet autoantigens in patients with abrupt onset type 1 diabetes and diabetes diagnosed with urinary glucose screening. J Autoimmun 1999;13:257-265 (Pubitemid 29436140)
13. Terasaki PI, Bernoco D, Park MS, Ozturk G, Iwaki Y. Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol 1978;69:103-120 (Pubitemid 8299128)
14. Kawabata Y, Ikegami H, Awata T, et al. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia 2009;52:2513-2521
15. Imagawa A, Hanafusa T, Uchigata Y, et al. Fulminant type 1 diabetes: a nationwide survey in Japan. Diabetes Care 2003;26:2345-2352 (Pubitemid 36993324)
16. Kawasaki E, Takino H, Yano M, et al. Autoantibodies to glutamic acid decarboxylase in patients with IDDM and autoimmune thyroid disease. Diabetes 1994;43:80-86
17. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral-induced macrophage production of TNF, IL-1, the procoagulant fgl2 prothrombinase and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160:3487-3493 (Pubitemid 28164743)
18. Wedemeyer H, Wiegand J, Cornberg M, Manns MP. Polyethylene glycol-interferon: current status in hepatitis C virus therapy. J Gastroenterol Hepatol 2002;17(Suppl. 3):S344-S350 (Pubitemid 35454309)
19. Nakamura K, Kawasaki E, Abiru N, et al. Trajectories of anti-islet autoantibodies before development of type 1 diabetes in interferon-treated hepatitis C patients. Case reports and a literature review. Endocr J 2010;57:947-951
20. Kuzushita N, Hayashi N, Moribe T, et al. Influence of HLA haplotypes on the clinical courses of individuals infected with hepatitis C virus. Hepatology 1998;27:240-244 (Pubitemid 28041560)
21. Huang X, Yuang J, Goddard A, et al. Interferon expression in the pancreases of patients with type I diabetes. Diabetes 1995;44:658-664
22. Stewart TA, Hultgren B, Huang X, Pitts-Meek S, Hully J, MacLachlan NJ. Induction of type I diabetes by interferon-alpha in transgenic mice. Science 1993;260:1942-1946 (Pubitemid 23258275)
23. Taki S. Type I interferons and autoimmunity: lessons from the clinic and from IRF-2-deficient mice. Cytokine Growth Factor Rev 2002;13:379-391
24. Fabris P, Floreani A, Tositti G, Vergani D, De Lalla F, Betterle C. Type 1 diabetes mellitus in patients with chronic hepatitis C before and after interferon therapy. Aliment Pharmacol Ther 2003;18:549-558 (Pubitemid 37186604)
25. Balasubramanyam A, Nalini R, Hampe CS, Maldonado M. Syndromes of ketosis-prone diabetes mellitus. Endocr Rev 2008;29:292-302 (Pubitemid 351679700)